

Remarks

Claims 1 and 3-6 stand rejected on the ground of non-statutory obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. patent No. 5,741,810.

Claims 1 and 3-6 stand rejected on the ground of non-statutory obviousness-type double patenting as being unpatentable over claims 1-28 of U.S. patent No. 6,248,773.

Claims 1 and 3-6 stand rejected on the ground of non-statutory obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. patent No. 6,160,129.

A terminal disclaimer was filed on October 13, 2010, which has been disapproved for using language which makes the terminal disclaimer indefinite.

Applicants are submitting duly completed Terminal Disclaimers for U.S. patent No. 5,741,810 and for U.S. patent No. 6,248,773 and for U.S. patent No. 6,160,129 against the present case.

In light of these Terminal Disclaimers, Applicants respectfully request the Office withdraw the rejection and issue a notice of allowance

If a telephone conference would advance prosecution of this application, the Examiner is invited to telephone the undersigned at 714 246 3217.

Respectfully submitted,

Date: November 10, 2010

/Doina G. Ene/
Doina G. Ene
Registration Number 62,615
Patent Agent of Record

Please direct all correspondence
and inquiries to:

Doina G. Ene, PhD
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92612
Tel: 714 246 3217
Fax: 714-246-4249